Authors
Latest:
Emulating target trials using observational evidence to inform clinical decision-making"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
Latest:
AUA 2024: Key Takeaways & Future of NMIBC ManagementGary D. Steinberg, MD, summarizes his major takeaway from the AUA 2024 conference and shares his insights on the potentially practice-changing developments he anticipates in the near future for the management of non-muscle-invasive bladder cancer (NMIBC).
Latest:
Prostate cancer survivor treated at MUSC shares his storyProstate cancer survivor Larry Ferguson, DMD, participated in a clinical trial at MUSC Hollings Cancer Center.
Latest:
Advice for limiting malpractice insurance costsExpert advice for physicians seeking new coverage.
Latest:
Kidney stone treatment inches toward precision medicine"As more genes are classified and catalogued, diagnosis and treatment of kidney stones inches further and further toward 'precision medicine,' " write Rutul Patel, DO, MS, and Alexander Small, MD.
Latest:
Fred Saad, MD, shares phase 3 ARANOTE findings by disease volume“Both groups benefited, but it would look like earlier is better if we can treat patients with low-volume disease,” says Fred Saad, MD, FRCS
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
Unsolved Mystery: Where did COVID-19 come from?Questions remain surrounding the origin of the global pandemic.
Latest:
ADT Treatment Considerations and Unmet Needs in Prostate CancerExperts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.
Latest:
Study shows gender disparities in CKD detection and treatment“We observed profound differences in the detection work up and management of chronic kidney disease suggesting suboptimal care among women,” said Juan Jesus Carrero, PharmD, PhD.
Latest:
Bladder Cancer Advocacy Network (BCAN) announces $600,000 in funding to accelerate breakthroughs in bladder cancer researchAwardees are being recognized for creative approaches to accelerating progress in bladder cancer research.
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
GNRH agonists vs antagonists in prostate cancer: How to chooseMany factors play into decision-making process when weighing agents.
Latest:
Andrew C. Peterson, MD, MPH, on counseling men regarding the artificial urinary sphincter"I think that now we have good data that patient-reported outcomes have to be considered in these patient populations," says Andrew C. Peterson, MD, MPH.
Latest:
Malpractice Consult: How attorneys successfully cross-examine expert witnesses"Effective cross-examination can create an implication that an expert’s opinions are motivated by bias or self-interest, rather than a neutral evaluation of the facts. This is frequently accomplished by highlighting the fact that experts are paid for time spent reviewing a case and testifying," writes Kenton H. Steele, Esq.
Latest:
Management of hormone-naïve oligometastatic prostate cancerGrowing evidence supports the existence of an intermediate metastatic disease state.
Latest:
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OABExperts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Latest:
Expert discusses the NMIBC trials landscape"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD.
Latest:
Study results affirm effectiveness of evolving prostate cancer therapies“I think it does give us confidence that clinical trials can predict how these drugs will work in the real world," says Stephen J. Freedland, MD.
Latest:
Insights on Perirectal Spacing in Prostate CancerIn the first article of this series, Juan Montoya, MD, discusses advances in perirectal spacing in the treatment of prostate cancer.
Latest:
Integrating video visits into urologic training"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Latest:
Taylor Goodstein, MD, highlights project on staging in larger kidney tumors“What we've been working on is a giant 30,000 patient database study using the National Cancer Database to see exactly what the rates are of upstaging and downstaging for these larger kidney tumors,” says Taylor Goodstein, MD.
Latest:
Clinical Pearls for Community Urologists Treating Patients with MIBCDr Chamie shares advice for community urologists treating patients with MIBC.
Latest:
PSMA PET-CT Imaging: Impact on Real-World Diagnosis and Management of Prostate CancerIn this companion article, Jaideep S. Sohi, MD, shares insights on PSMA-PET imaging’s impact on real-world diagnosis and management of prostate cancer.
Latest:
US Urology Partners Names Healthcare Visionary Raoul S. Concepcion, MD, as Chief Science OfficerConcepcion is editor-in-chief of Urology Times' sister publication, Urologists in Cancer Care.
Latest:
Letter: Declassifying Gleason 6 as a cancer would do more harm than good"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Latest:
Future Horizons in PSMA-Targeted Imaging and the Management of Prostate CancerExperts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
Latest:
Does varicocele affect prostate cancer outcomes?"We found that with a 5-year Kaplan-Meier survival analysis that patients with varicocele had worse outcomes than patients without varicocele," says Muhammed A. Moukhtar Hammad, MBBCh.
